Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer-Reference-Cited by-同舟云学术

Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer

Published:2009-01 Issue:1 Volume:12 Page:124-129
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Cella David,Nichol Michael B.,Eton David,Nelson Joel B.,Mulani Parvez

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference28 articles.

1. Quality-of-life evaluation in patients receiving treatment for advanced prostate cancer;Esper;Oncol Nurs Forum,1999

2. The importance of quality-of-life endpoints in clinical trials to the practicing oncologist;Passik;Hematol Oncol Clin North Am,2000

3. Chemotherapy in advanced non-small cell lung cancer;Splinter;Eur J Cancer,1990

4. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT–L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592;Cella;J Clin Epidemiol,2002

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of Life Determinants in Patients with Metastatic Prostate Cancer: Insights from a Cross-Sectional Questionnaire-Based Study;Current Oncology;2024-08-26

2. Symptom burden among men treated for castration-resistant prostate cancer: a longitudinal study;BMJ Supportive & Palliative Care;2024-08-08

3. Optimizing assessments of quality of life in contemporary prostate cancer clinical trials;Cancer;2024-07-27

5. Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy;BJU International;2024-06-28